



Gene4Neuro

PROGRAM



2 – 4 June 2026



Pamplona, Spain

THE DECISION-MAKER SUMMIT FOR LEADERS IN GENE THERAPY - RARE NEUROLOGICAL DISEASES & NEURODEGENERATION

Key Opinion Leaders
Startups Founders
C-level Executives
Industry Executives
Investors

HOST PARTNER
& CO-ORGANIZER



SPONSORS
& PARTNERS



STRATEGIC
PARTNER



AN INITIATIVE OF



PROGRAMME OVERVIEW

PROGRAMME

All sessions are plenary and participatory — to spark discussion, not replace it. All participants are able to engage in the discussions.

2 JUNE

SPEAKERS & PARTNERS WELCOME DAY

16:30

Private VIP Tour — University of Navarra Museum of Modern Arts

Speakers & Partners

17:30

Welcome Reception — Tapas & Wine at the Museum

Speakers & Partners

3 JUNE

DAY I — SCIENCE, PATIENTS & CAPITAL

09:00

Coffee & Registration

09:15

Welcome & Opening Remarks

Christian J. Suojanen, CEO – Broadreach Global · Chairman, Bio-Neuroscience Initiative

José Luís Lanciego, Head, Laboratory of Gene Therapy for Parkinson's Disease – CIMA, University of Navarra · President, European Brain Foundation

09:30

KEYNOTE I

Disease-Modifying Trials in Parkinson's Disease: Design, Challenges, and Opportunities

Charalampos Tzoulis, Professor of Neurology & Neurogenetics, University of Bergen / Haukeland University Hospital · Director, Neuro-SysMed Centre of Excellence · Director, K.G. Jebsen Centre for Translational Research in Parkinson's Disease

10:15

PANEL

Engineering Novel Capsids for CNS Transduction

MODERATOR

José Luís Lanciego, Head, Lab of Gene Therapy for Parkinson's Disease – CIMA, Univ. Navarra

TALKS & PANEL

"Vectorized Antibody for the Treatment of ALS — Development, Challenges & Innovations"

Giulia de Sabbata, Director & Head of Discovery – VectorY Therapeutics

“Gene Therapy for a Rare Mitochondrial Genetic Disorder, COXPD1”

Diego Herrero Martinez, CIMA, Univ. Navarra

“Cross-Species Inner Ear AAV Capsid Screening for Sensorineural Hearing Loss”

Carmen Unzu, Group Leader, Ramón y Cajal Investigator, DNA & RNA Medicine Division – CIMA, University of Navarra

11:00 Coffee Break

11:30 **PANEL** **BBB-Penetrating Modalities Beyond Gene Therapy**

Antibodies, ASOs, brain shuttles, RNA-based approaches

PANEL

Nuno Pires, Senior Manager, Rare Diseases & New Modalities – Bial

Pablo Sardi, Global Head, Rare & Neurologic Diseases Therapeutic Area – Sanofi

Toshal Patel, VP & Head of Scientific Search, Evaluation and Partnering – UCB

Gergely Tóth, Chief Executive & Scientific Officer, Founder – CANTABio

12:15 **PANEL** **The Patients’ Voice — Rare Disease Innovation**

MODERATOR

Christian J. Suojanen, CEO – Broadreach Global

TALKS & PANEL

“First Patient Dosing in Pitt Hopkins Syndrome: A Milestone and What It Means for the Field”

Yael Weiss, CEO – Mahzi Therapeutics

“NEDAMSS, First Patient Dosing in a Record 10 Months; Expanding the Trial Internationally”

Kathrin Meyer, Chief Scientific Officer – Neela Therapeutics · Board Member – Ellys Team Foundation

“Patient Power in Research: How France Parkinson Drives Gene Therapy Priorities”

Marie Fuzzati Armentero, Directrice Scientifique – France Parkinson

13:00 Networking Lunch

14:15 **KEYNOTE II** **Pioneering Gene Therapy Strategies for Neurodegenerative Diseases**

Nathalie Cartier Lacave, Member, French Academy of Medicine · President, HelilixBio Therapeutics

15:00 **PANEL** **Rare CNS Disorders**

MODERATOR

Gloria González-Asequinolaza, Program Director – CIMA, Universidad de Navarra · Co-Founder & CSO – Amets Biotechnology

TALKS & PANEL

“AVB-406 for the Treatment of Tauopathies”

Graeme Fielder, Chief Operating Officer – AviadoBio

“Rare Neurogenetic Disease: Insights from Institute La Fe and CIBERER”

José María Millán Salvador, Health Research Institute La Fe, Valencia · CIBERER

Adolfo López de Munain, Scientific Director – CIBERned · Head of Neurology – Hospital Universitario Donostia · CMO – Miramoon Pharma

“Gene Therapy for Congenital Encephalopathies”

Ruben Hernandez, Principal Investigator – CIMA, University of Navarra

15:45

Coffee Break

16:15

PANEL

The Roadmap: From Rare Monogenic to Complex Polygenic CNS Disease

Pricing, durability and patient selection

TALKS & PANEL

“Sanofi’s Rare & Neurologic Gene Therapy Priorities — What Comes Next”

Pablo Sardi, Global Head, Rare & Neurologic Diseases Therapeutic Area – Sanofi

“AAV.E2F4DN: A Translational Gene Therapy Approach for Alzheimer’s Disease and Beyond”

José María Frade, Co-Founder & CSO – Tetraneuron · Group Leader – Instituto Cajal, CSIC

Erwan Bezar, Chief Executive & Scientific Officer – Motac Neuroscience · Co-Founder, Treefrog Therapeutics & SE Therapeutics

17:00

PANEL

The Capital Calculus — Investing in CNS Gene Therapy

MODERATOR

Christian J. Suojanen, CEO – Broadreach Global

PANEL

Emilio Erazo-Fischer, Operating Partner – Asabys Partners · CBO – ALLOX

Cinta Díez, Investment Associate – InVivo Partners

17:45

End of Day | 18:00 Tapas & Wine Networking Reception

— E N D O F D A Y I —

Day II begins on the next page

P R O G R A M M E · D A Y I I

PROGRAMME

4 JUNE

DAY II — TRANSLATION, INDUSTRY & CLOSING

08:30 Coffee & Registration

09:00 **Welcome & Day 2 Opening Remarks**

Christian J. Suojanen, CEO – Broadreach Global · Chairman, Bio-Neuroscience Initiative

José Luís Lanciego, Head, Laboratory of Gene Therapy for Parkinson's Disease – CIMA, University of Navarra · President, European Brain Foundation

09:15 **KEYNOTE III** **Building the Bridge: Practical Pathways from Academic Discovery to CNS Gene Therapy**

Opher Kornfeld, Director, Translational Research and Development – SPARK NS

10:00 **PANEL** **Targeting CNS Degenerative Disorders**

MODERATOR

Nathalie Cartier Lacave, Member, French Academy of Medicine · President, HelilixBio Therapeutics

TALKS & PANEL

“What Preclinical Models Are Telling Us — and Where They Still Fall Short”

Erwan Bezar, Chief Executive & Scientific Officer – Motac Neuroscience · Co-Founder, Treefrog Therapeutics & SE Therapeutics

“Miramoon Pharma — Novel Therapeutic Approaches for Neurodegenerative Disease”

Adolfo López de Munain, CMO – Miramoon Pharma · Scientific Director – CIBERned · Head of Neurology – Hospital Universitario Donostia

“AMT-130 in Huntington's Disease: Data Update and Field Implications”

Richard Porter, CSO & CBO – uniQure

11:00 Coffee Break

11:30 **PANEL** **Scaling for the Clinic — De-Risking Gene Therapy through CMC and Regulatory Strategy**

TALKS

César Trigueros, Chief Scientific Officer – Viralgen

Mimoun Azzouz, *Founder & Director – Gene Therapy Innovation & Manufacturing Centre (GTIMC)*
 · *Chair of Translational Neuroscience – University of Sheffield* · *Co-Founder – Crucible Therapeutics* · *Founding Director – BlackfinBio*

MODERATOR

Yael Weiss, *CEO – Mahzi Therapeutics*

ROUND-TABLE DISCUSSION

12:30

PANEL Concluding Round-Table Discussions with the Full Audience

Challenges, Lessons Learned, Key Messages and Priorities for the Way Forward

MODERATORS

Christian J. Suojanen, *CEO – Broadreach Global*

José Luís Lanciego, *Head, Laboratory of Gene Therapy for Parkinson's Disease – CIMA, University of Navarra* · *President, European Brain Foundation*

13:15

Closing Remarks & End of Summit

José Luís Lanciego, *Head, Laboratory of Gene Therapy for Parkinson's Disease – CIMA, University of Navarra* · *President, European Brain Foundation* — *Scientific synthesis and field outlook*

Christian J. Suojanen, *CEO – Broadreach Global* — *Forward-looking close, white paper announcement & Gene4Neuro community next steps*

13:30

Transport to Speakers Closing Wine Pairing Lunch at Bodegas Arínzano — one of Spain's historic Vinos de Pago estates

14:00

Closing Wine Pairing Lunch — Speakers & Partners — Bodegas Arínzano

*One of Spain's historic **Vinos de Pago** estates, dating to 1055, in the Navarran countryside roughly 30 minutes from Pamplona.*

I N S I G H T · A C C E S S · E N G A G E M E N T · I M P A C T

An Initiative of Broadreach Global · Co-organised with CIMA, University of Navarra